Claims for Patent: 11,260,053

Summary for Patent: 11,260,053

Title:	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
Abstract:	Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
Inventor(s):	Gedulin; Bronislava (Del Mar, CA), Young; Andrew A. (Chapel Hill, NC), Greene; Howard E. (Frankfort, MI)
Assignee:	SATIOGEN PHARMACEUTICALS, INC. (San Diego, CA)
Application Number:	16/276,540
Patent Claims:	1. A method of increasing the concentration of bile acids and salts thereof in the distal gastrointestinal tract of an individual comprising administering an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) to the individual, wherein a therapeutically amount of the ASBTI is delivered to the distal ileum, the colon, or the rectum of an individual in need thereof, wherein the ASBTI is selected from ##STR00072## and potassium((2R,3R,4S,5R,6R)-4-benzyloxy-6-{3-[3-((3S,4R,5R)-3-butyl-7-dime- thylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]thiepi- n-5-yl)-phenyl]-ureido}-3,5-dihydroxy-tetrahydropyran-2-ylmethyl)sulphate ethanolate hydrate. 2. The method of claim 1, further comprising administering a second agent selected from an enteroendocrine peptide enhancing agent, a nuclear farnesoid X receptor (FXR) agonist, a liver receptor homolog 1 (LRH-1), a DPP-IV inhibitor, a proton pump inhibitor, H2 antagonist, prokinetic agent, a biguanide, an incretin mimetic, a thiazolidinone, a mucoadhesive agent, and GLP-1 or an analog thereof. 3. The method of claim 1, wherein the individual is a prematurely born infant, an enterally-fed infant, or a formula-fed infant. 4. The method of claim 1, wherein the ASBTI reduces intraenterocyte bile acids or reduces necrosis and/or damage to ileal architecture in an individual in need thereof. 5. The method of claim 2, wherein the enteroendocrine peptide enhancing agent is a bile acid, a bile salt, a bile acid mimic, a bile salt mimic, or a combination thereof, optionally wherein the bile acid or the bile acid mimic is cholic acid, deoxycholic acid, glycocholic acid, glycodeoxycholic acid, taurocholic acid, taurodihydrofusidate, taurodeoxycholic acid, cholate, glycocholate, deoxycholate, taurocholate, taurodeoxycholate, chenodeoxycholic acid, a TGR5-binding analog, M-BAR agonist, GPR119 agonist, GPR120 agonist, GPR131 agonist, GPR140 agonist, GPR143 agonist, GPBAR1 agonist, BG37 agonist, FXR agonist, 6-methyl-2-oxo-4-thiophen-2-yl-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid benzyl ester, INT-777, RG-239, oleanolic acid, or crataegolic acid, or a compound represented by Formula (VII): ##STR00073## wherein: each R.sup.1 is independently H, OH, lower alkyl, or lower heteroalkyl; L is a substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl; each R.sup.2 is independently H, OH, lower alkyl, or lower heteroalkyl; R.sup.3 is H, OH, O-lower alkyl, lower alkyl, or lower heteroalkyl; A is COOR.sup.4, S(O).sub.nR.sup.4, or OR.sup.5; R.sup.4 is H, an anion, a pharmaceutically acceptable cation, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an amino acid; n is 1-3; R.sup.5 is lower alkyl or H; or a salt thereof. 6. The method of claim 2, wherein the FXR agonist is GW4064, GW9662, INT-747, T0901317, WAY-362450, fexaramine, cholic acid, deoxycholic acid, glycocholic acid, glycodeoxycholic acid, taurocholic acid, taurodihydrofusidate, taurodeoxycholic acid, cholate, glycocholate, deoxycholate, taurocholate, taurodeoxycholate, chenodeoxycholic acid, or a salt thereof, or a combination thereof. 7. The method of claim 2, wherein the ASBTI and/or the second agent is administered before ingestion of food. 8. The method of claim 2, wherein the ASBTI and/or the second agent is administered less than about 60 minutes before ingestion of food. 9. The method of claim 2, wherein the ASBTI and/or the second agent is administered less than about 30 minutes before ingestion of food. 10. The method of claim 2, wherein the ASBTI and/or the second agent is administered orally. 11. The method of claim 2, wherein the ASBTI and/or the second agent is administered orally as an ileal-pH sensitive release or an enterically coated formulation. 12. The method of claim 2, wherein the ASBTI is ##STR00074## 13. The method of claim 2, wherein the ASBTI is potassium((2R,3R,4S,5R,6R)-4-benzyloxy-6-{3-[3-((3S,4R,5R)-3-butyl-7-dime- thylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]thiepi- n-5-yl)-phenyl]-ureido}-3,5-dihydroxy-tetrahydropyran-2-ylmethyl)sulphate ethanolate hydrate, or a pharmaceutically acceptable salt or solvate thereof. 14. The method of claim 1, wherein the subject does not have diabetes. 15. The method of claim 1, wherein the ASBTI is administered before ingestion of food. 16. The method of claim 1, wherein the ASBTI is administered less than about 60 minutes before ingestion of food. 17. The method of claim 1, wherein the ASBTI is administered less than about 30 minutes before ingestion of food. 18. The method of claim 1, wherein the ASBTI is administered orally. 19. The method of claim 1, wherein the ASBTI is administered orally as an ileal-pH sensitive release or an enterically coated formulation. 20. The method of claim 1, wherein the ASBTI is ##STR00075## 21. The method of claim 1, wherein the ASBTI is potassium((2R,3R,4S,5R,6R)-4-benzyloxy-6-{3-[3-((3S,4R,5R)-3-butyl-7-dime- thylamino-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]thiepi- n-5-yl)-phenyl]-ureido}-3,5-dihydroxy-tetrahydropyran-2-ylmethyl)sulphate ethanolate hydrate, or a pharmaceutically acceptable salt or solvate thereof.